Foghorn Therapeutics (NASDAQ:FHTX – Get Free Report)‘s stock had its “buy” rating reiterated by research analysts at HC Wainwright in a report released on Wednesday, Benzinga reports. They presently have a $20.00 price objective on the stock. HC Wainwright’s target price indicates a potential upside of 266.30% from the stock’s current price. Separately, Wedbush reissued […]